PACIFIC BIOSCIENCES CALIF IN's ticker is PACB and the CUSIP is 69404D108. A total of 215 filers reported holding PACIFIC BIOSCIENCES CALIF IN in Q4 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $1,594,000 | +107.8% | 61,440 | -21.0% | 0.35% | +75.2% |
| Q3 2020 | $767,000 | +148.2% | 77,750 | -13.1% | 0.20% | +124.4% |
| Q2 2020 | $309,000 | +317.6% | 89,500 | +271.4% | 0.09% | +233.3% |
| Q1 2020 | $74,000 | -52.9% | 24,100 | -21.0% | 0.03% | -43.8% |
| Q4 2019 | $157,000 | -13.3% | 30,500 | -12.9% | 0.05% | -20.0% |
| Q3 2019 | $181,000 | -79.5% | 35,000 | -71.3% | 0.06% | -80.3% |
| Q1 2019 | $881,000 | -36.3% | 121,890 | -34.8% | 0.30% | -46.3% |
| Q4 2018 | $1,383,000 | -45.4% | 186,924 | -60.1% | 0.57% | -35.5% |
| Q3 2018 | $2,532,000 | +66.5% | 467,961 | +9.2% | 0.88% | +52.2% |
| Q2 2018 | $1,521,000 | +63.2% | 428,461 | -5.8% | 0.58% | +53.1% |
| Q1 2018 | $932,000 | +505.2% | 454,671 | +678.5% | 0.38% | +480.0% |
| Q4 2017 | $154,000 | +20.3% | 58,400 | +73.8% | 0.06% | -15.6% |
| Q4 2016 | $128,000 | – | 33,600 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,660,000 | $24,206,000 | 11.49% |
| Data Collective II GP, LLC | 164,249 | $1,495,000 | 5.44% |
| Decheng Capital Management III (Cayman), LLC | 1,463,872 | $13,321,000 | 4.08% |
| SB Management Ltd | 1,886,107 | $17,164,000 | 3.33% |
| Casdin Capital, LLC | 7,990,652 | $72,715,000 | 3.26% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,225,395 | $11,151,000 | 2.20% |
| Jackson Square Partners, LLC | 22,542,589 | $205,137,000 | 2.04% |
| BOURNE LENT ASSET MANAGEMENT INC | 556,865 | $5,067,000 | 1.59% |
| ARK Investment Management | 27,259,521 | $248,062,000 | 1.04% |
| Nikko Asset Management Americas, Inc. | 14,021,205 | $127,873,000 | 0.94% |